Ad
Tuesday, 22 November 2016
FDA lifts hold on AstraZeneca head and neck cancer trials
LONDON (Reuters) - U.S. officials have given a green light for two clinical trials testing AstraZeneca's cancer immunotherapy drug durvalumab in head and neck cancer to resume recruiting patients, lifting a hold imposed following cases of bleeding.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment